RecruitingNCT07532213

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

Long-Term Use of Guselkumab: Non-interventional Assessment of Real-world Outcomes

Sponsor

Janssen-Cilag A.G., Switzerland

Enrollment

50 participants

Start Date

Apr 13, 2026

Study Type

OBSERVATIONAL

Conditions

Crohn Disease Inflammatory Bowel Disease Colitis Ulcerative

Summary

The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with colitis ulcerative, crohn disease, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.